Sandoz TV Episode 17: Trailer
Find out what to expect from the newest episode of Sandoz TV.
|Global News||Sandoz Around the World||Sandoz in the Media|
FDA accepts Sandoz application for biosimilar filgrastim
Holzkirchen, July 24, 2014
Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application for filgrastim.
Sandoz obtains rights in US to commercialize KERYDINTM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.
Princeton, New Jersey, July 21, 2014
Sandoz today announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize Anacor’s drug KERYDINTM (tavaborole) topical solution.
Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook
July 17, 2014
Sandoz launches authorized generic version of TOBI®
July 14, 2014
Sandoz today announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI®, currently marketed by Novartis Pharmaceuticals Corporation 1.
Sandoz's Joerg Windisch Reelected as Chair of EGA’s European Biosimilars Group
July 09, 2014
Today, Sandoz announced that the European Generic medicines Agency (EGA) has reelected Dr. Joerg Windisch, Chief Science Officer at Sandoz, as chair of its European Biosimilars Group (EBG).